Water treatment plants play a major role in the cycle of water recovery and reuse. Besides the benefits of water treatment plants, they have a great impact on the environment, social life, economy, and natural habitats. In this sense, decision-makers should effectively plan the construction and operational activities of plants, taking into account the expectations of users. Growing public expectations about water treatment plants increase the pressures on investors and government managers. In this study, we focus on defining and determining the weights of public expectations from water treatment plants and handle as a multi-criteria decision-making problem. A two-level hierarchical model is structured to evaluate public expectations from water treatment plants as model criteria. For the problem, a literature review is performed to search the main criteria. The most suitable criteria for the problem are determined using experts' opinions. Then, the sub-criteria are determined. Experts' evaluations are collected by face to face interviews. These evaluations are consolidated and finalized via the modified Delphi method. Trapezoidal Type-2 Fuzzy Analytic Hierarchy Process (T2F-AHP) is employed to determine criteria weights using results obtained by the modified Delphi method. A sensitivity analysis is performed to show the reliability of the proposed methodology. https://www.selleckchem.com/products/OSI-906.html A comparison is also performed between the Analytic Hierarchy Process (AHP) and the proposed methodology. The results of this study can be used as a guide to develop public strategies about water treatment plants. Finally, conclusions and future directions of this work are given. Vasospastic angina (VSA) reportedly accounts for one form of sudden cardiac arrest (SCA). Intracoronary acetylcholine (ACh) testing is useful for diagnosing VSA although invasive provocation testing after SCA is a clinical challenge. In addition, even if the ACh test is positive, any causal relationship between VSA and SCA is often unclear because patients with VSA may have other underlying cardiac disorders. A total of 20 patients without overt structural heart disease who had been fully resuscitated from SCA were included. All patients underwent the ACh provocation test and scrutiny such as cardiac computed tomography or magnetic resonance imaging. Patients were followed up for all-cause death or recurrent SCA including appropriate implantable cardioverter defibrillator therapy. An ACh provocation test was performed 20 ± 17days after cardiac arrest. Fifteen out of 20 (75.0%) patients had a positive ACh test and 2 (10.0%) had adverse events such as ventricular tachycardia and transient cardiogenic shock during the test. In patients with a positive ACh test, 6 of 15 (40.0%) patients had other overlapping cardiac disorders such as long QT syndrome, Brugada syndrome, cardiac sarcoidosis, myocarditis, or cardiomyopathy. Long-term prognosis was not different regardless of a positive ACh test or the presence of other cardiac disorders overlapping with VSA. Three-quarters of the patients who had been resuscitated from SCA had a positive ACh test. Further examinations revealed other overlapping cardiac disorders in addition to VSA in 40% of patients with a positive ACh test. Three-quarters of the patients who had been resuscitated from SCA had a positive ACh test. Further examinations revealed other overlapping cardiac disorders in addition to VSA in 40% of patients with a positive ACh test.In spite of the introduction of numerous new antiseizure drugs (ASD) over the last decades, the percentage of drug-resistant epilepsies has remained almost stable. To achieve seizure freedom in such patients with any modified ASD regimen is an exception. Cenobamate (CNB) is a new ASD that showed unusually high efficacy in the pivotal placebo controlled, randomized trials. In both studies (C013 and C017), the rate of seizure-free patients was sometimes more than 20% and thus in a range never reached over the last decades in comparable trials with other new ASDs. This suggests that CNB which is already approved in the USA might actually offer a new and encouraging perspective for epilepsy treatment concerning efficacy. In this review the pharmacological profile, the currently known mode of action, and the results of the clinical trials are summarized. Muscle cramps are suddenly occurring involuntary, mostly painful contractions of a single muscle, rarely of amuscle group. They can be idiopathic or occur in various neuromuscular diseases and can sometimes substantially impair the quality of life due to the frequency and strength. Only afew drugs are available for the effective treatment of cramps. In this case series we report on five patients with cramps of different origin who responded well to treatment with brivaracetam. Brivaracetam is actually used for the treatment of epileptic seizures. It binds to the synaptic vesicle protein 2A (SV2A), which also occurs in nerves and nerve roots. The SV2A regulates the exocytotic release of neurotransmitters, which could explain the effect of brivaracetam on muscle cramps. Further studies are needed to demonstrate the effect of brivaracetam on muscle cramps. Further studies are needed to demonstrate the effect of brivaracetam on muscle cramps. Clinical positron emission tomography (PET) imaging of the presynaptic norepinephrine transporter (NET) function provides valuable diagnostic information on sympathetic outflow and neuronal status. As data on the NET-targeting PET tracers [ C]meta-hydroxyephedrine ([ C]mHED) and [ F]LMI1195 ([ F]flubrobenguane) in murine experimental models are scarce or lacking, we performed a detailed characterization of their myocardial uptake pattern and investigated [ C]mHED uptake by kinetic modelling. [ C]mHED and [ F]LMI1195 accumulation in the heart was studied by PET/CT in FVB/N mice. To test for specific uptake by NET, desipramine, a selective NET inhibitor, was administered by intraperitoneal injection. [ C]mHED kinetic modelling with input function from an arteriovenous shunt was performed in three mice. Both tracers accumulated in the mouse myocardium; however, only [ C]mHED uptake was significantly reduced by excess amount of desipramine. Myocardial [ C]mHED uptake was half-saturated at 88.3nmol/kg of combined mHED and metaraminol residual.